Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning global outbreak modeling and vector dynamics, novel therapeutic strategies for chronic viral and bacterial infections, and emerging diagnostic and environmental health insights. Let's dive in.

This week's papers:

1. Size of the 2026 Ebola outbreak and risk of cross-border spillover from Bundibugyo virus in Ituri Province, DR Congo, and its implications for preparedness: a recalibrated stochastic modelling study. — The Lancet. Infectious diseases 2026
2. The origin, history, and resistance architecture of an invasive urban malaria mosquito in Africa. — Science 2026
3. A Streptomyces megacluster encodes synergistic biotin-targeting antibiotics. — Nature 2026
4. Prevalence and epidemiological patterns of Neisseria gonorrhoeae infection in sub-Saharan Africa, 1964-2025: Systematic review, meta-analyses, and meta-regressions. — PLoS medicine 2026
5. Klebsiella genus as driver of human disease: from infections to non-communicable disorders. — Nature reviews. Microbiology 2026
6. FDG-PET/CT Demonstrates Superior Detection of Multiorgan Involvement in Paracoccidioidomycosis Compared with Conventional Staging. — Clinical infectious diseases 2026
7. WHO estimates of the global, regional, and national disease burden of nine foodborne chemicals, 2000-21: an updated data synthesis. — The Lancet. Global health 2027
8. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. — The New England journal of medicine 2026
9. Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study. — The Lancet. Infectious diseases 2026
10. An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut. — Cell 2026

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning major clinical trials in bacterial infections, new data on vaccine effectiveness for COVID-19 and Mpox, and a look at the future of antimicrobial discovery and global disease surveillance. Let's dive in.

This week's papers:

1. An HIV vaccine blueprint. — Science (New York, N.Y.) 2026
2. Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study. — The Lancet. Infectious diseases 2026
3. Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
4. Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae. — Science translational medicine 2026
5. Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections. — Science translational medicine 2026
6. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. — JAMA internal medicine 2026
7. Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource. — Nature 2026
8. WHO estimates of the global, regional, and national burden of 14 foodborne diarrhoeal enteric hazards, 2000-21: an updated data synthesis. — The Lancet. Global health 2026
9. Identification of host gene transcripts by machine learning and their application to predict outcome in Ebola virus disease. — The Journal of infectious diseases 2026

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning practical hospital-based infection control, the intricacies of host-virus interactions, and the latest in global health epidemiology and policy. Let's dive in.

This week's papers:

1. Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
2. SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire. — Science translational medicine 2026
3. GPR15-guided CD8T regulatory cells control intestinal inflammation. — Nature 2026
4. Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries. — The Lancet. Global health 2026
5. Inclusion of young adolescents in policy development for new tuberculosis vaccines. — The Lancet. Global health 2026
6. Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia. — The Lancet. Infectious diseases 2026
7. Zoster Vaccination and Dementia: Interpreting the Signal and Testing the Mechanisms. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
8. Molecular Epidemiology to Decipher the Transmission Networks of MPOX in an Outbreak Scenario: Applications in Thailand during the 2023 Global Health Emergency. — The Journal of infectious diseases 2026
9. Implementing the commitments of the World Health Assembly kidney health resolution: a key opportunity to improve health for millions. — Lancet (London, England) 2026
10. Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cells. — Cell 2026

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning the global fight against antimicrobial resistance, new insights into host immunology and viral reservoirs, and key updates in prevention and therapeutics. We'll also note two important dispatches from the field on drug-resistant malaria and the Sudan Virus. Let's dive in.

This week's papers:

1. Global, regional, and national impact of the Expanded Programme on Immunization against 14 pathogens from 1974 to 2024: an economic evaluation. — The Lancet. Global health 2026
2. Plasma signals of lung tumor promotion for molecular cancer prevention. — Cell 2026
3. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. — JAMA 2026
4. A natural depsipeptide antibiotic binds the E-site of the bacterial ribosome. — Nature 2026
5. Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy. — The New England journal of medicine 2026
6. Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda. — The New England journal of medicine 2026
7. Sudan Virus Disease in Uganda, 2025. — The New England journal of medicine 2026
8. HIV-1 infection converts CD4T cells to HLA class II-restricted CD8T cells. — Science translational medicine 2026
9. Limitations of Global Surveillance for Neisseria gonorrhoeae Antimicrobial Resistance. — Emerging infectious diseases 2026
10. Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development. — The Lancet. Infectious diseases 2025

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning diagnostics and stewardship, new therapies for major global infections, and key updates in public health and epidemiology. Let's dive in.

This week's papers:

1. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
2. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. — The New England journal of medicine 2026
3. Sustained and indirect effects of PCV10 reduced-dose schedules on pneumococcal carriage in Viet Nam: a long-term follow-up of a cluster-randomised controlled trial. — The Lancet. Infectious diseases 2026
4. Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993-2025: A systematic review and meta-analysis. — PLoS medicine 2026
5. U = U for all: Advancing equity in HIV prevention. — PLoS medicine 2026
6. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. — JAMA 2026
7. A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study. — The Lancet. Infectious diseases 2026
8. Varicella zoster virus and the central nervous system. — Nature reviews. Microbiology 2026
9. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. — The Lancet. Infectious diseases 2026
10. Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia. — The Lancet. Infectious diseases 2025

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 8 notable papers spanning advances in HIV prevention and management, antimicrobial stewardship in common outpatient infections, and the global landscape of surveillance, new drugs, and prevention. Let's dive in.

This week's papers:

1. Global and regional molecular epidemiology of HIV-1 during 1990-2024: systematic review, global survey, and analysis of prevalence. — The Lancet. Infectious diseases 2026
2. Azithromycin for Preschoolers with Wheezing in the Emergency Department. — The New England journal of medicine 2026
3. Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
4. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
5. Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study. — Lancet (London, England) 2026
6. Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. — Lancet (London, England) 2026
7. Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults. — JAMA 2026
8. Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026

Listen at AudioScholar

Welcome to This Week in Infectious Disease. This week we're covering 8 notable papers spanning global health prevention, neonatal sepsis, and the evolving landscape of viral infections. Let's dive in.

This week's papers:

1. Understanding and exploiting superspreading to disrupt Mycobacterium tuberculosis transmission. — The Lancet. Infectious diseases 2026
2. Post-mortem characterisation of pathogen-specific causes of infection-related deaths in African and south Asian neonates: a prospective, observational, multicentre study. — The Lancet. Infectious diseases 2026
3. Sex-specific presentation, epidemiology, and control of schistosomiasis in women and adolescent girls. — The Lancet. Global health 2026
4. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts. — The New England journal of medicine 2026
5. Contribution of nosocomial transmission to Klebsiella pneumoniae neonatal sepsis in Africa and South Asia: An observational study of infection clusters inferred from pathogen genomics and temporal data. — PLoS medicine 2026
6. Global, regional, and national estimates of tuberculosis incidence averted by eliminating undernutrition in adults: a modelling study. — The Lancet. Global health 2026
7. Impact of introducing RTS,S/AS01malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme. — Lancet (London, England) 2026
8. Respiratory viral infections prime accelerated lung cancer growth. — Cell 2026

Listen at AudioScholar